![Enlivex Therapeutics Ltd. logo](/logos/ENLV.webp)
Enlivex Therapeutics Ltd.
NASDAQ:ENLV
Overview | Financials
Company Name | Enlivex Therapeutics Ltd. |
Symbol | ENLV |
Currency | USD |
Price | 1.27 |
Market Cap | 26,507,186 |
Dividend Yield | 0% |
52-week-range | 1.15 - 4.59 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Mr. Shai Novik M.B.A. |
Website | https://www.enlivex.com |
An error occurred while fetching data.
About Enlivex Therapeutics Ltd.
Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. Enlivex Therapeutics Ltd. was founded in
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD